StreetAlpha.app
Home › Stocks › ANIX

Anixa Biosciences Inc (ANIX)

$2.67
▲ +4.71%
LAST CLOSE · NOV 17

Anixa Biosciences develops cancer therapies and vaccines, mainly for ovarian and breast cancer, and is based in San Jose, California. It last closed at $2.67 on Nov 17, up 4.71% on the day. ANIX reports earnings on Mon, Jan 11, 2027.

AI Auto Pilots
Is ANIX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$10.4M
EPS (diluted)
−$0.32
Valuation
Market cap
$92.8M
34.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.4M
At Jul 31
Shareholder equity
$14.5M
Shares outstanding
34.8M
At Sep 9
Fiscal year endsOctober
ExchangeNasdaq
Financials history
FY2021: −$13.0M−$13.0MFY2021FY2022: −$13.6M−$13.6MFY2022FY2023: −$9.8M−$9.8MFY2023FY2024: −$12.6M−$12.6MFY2024FY2025: −$10.9M−$10.9MFY2025

From ANIX's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 9). Last 12 months adds up the four latest quarters.

Next report
Jan 11
2027 · Time not announced
Consensus EPS forecast
-$0.08
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ANIX in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 124.7% upside

Based on 1 analyst who set a price target on ANIX in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $2.67.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $2.67
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
HC Wainwright & Co.Maintained
Sep 22Buy$6
D. Boral CapitalAssumed coverage
Jun 30Buy$10
DateFirmActionRatingPrice target
Sep 22HC Wainwright & Co.MaintainedBuy$6
Jun 30D. Boral CapitalAssumed coverageBuy$10
Loading…

Technical Analysis

ANIX · as of the Nov 17 close · updated after every close
Downtrend

The stock is 11% below its 20 day and 7% below its 50 day average. It is 11% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the swing low (Sep 10) at $2.66, and the nearest resistance the Pivot R1 at $2.74.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 7.1%/day
Key levels
$5.4652 week high+104.5%
$3.10100 day average+16.1%
$2.9820 day average+11.6%
$2.95200 day average+10.5%
$2.8650 day average+7.1%
$2.82Swing high (May 22)+5.6%
$2.74Pivot R1+2.6%
$2.67Last close
$2.66Swing low (Sep 10)−0.4%
$2.65Pivot−0.7%
$2.57Pivot S1−3.7%
$2.3252 week low−13.1%
Indicators
RSI (14)42.22Middle of its rangeNeutral
MACD-0.06Below its signal lineBearish
Stochastic7.1Near the bottom of its rangeOversold
ADX (14)22.2Weak trend
Williams %R-85.6Oversold below −80, overbought above −20Oversold
CCI (20)-110.9Oversold below −100, overbought above 100Oversold
Rate of change−12.6%Change over 10 sessionsBearish
ATR (14)$0.19Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANIX

What happened before

See how ANIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ANIX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ANIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ANIX in the last 90 days.

Loading…

See today’s whale options flow across the market →

ANIX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲34 buying vs 13 selling
  • ▲Held by funds +2.9 pts
  • ▲Funds holding +11
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7564+17.2%
In funds' top 1000–
Held by funds18.4%15.4%+2.9 pts
New / increased14 / 2011 / 16+25.9%
Reduced / sold out9 / 47 / 7−7.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANIX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANIX is in one of them and how their past ANIX trades turned out.

ANIX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANIX in an article yet. Here's the latest on the wider market.

About Anixa Biosciences

Anixa Biosciences is a biotechnology company based in San Jose, California, that is developing cancer therapies and vaccines. Its main programs focus on ovarian cancer and breast cancer, including a cell therapy designed to treat ovarian cancer and a vaccine aimed at preventing and treating breast cancer. Its products are still being tested in clinical trials and are not yet available for sale.

Headquarters
San Jose, CA